Irritable Bowel Syndrome Characterized by Constipation Completed Phase 2 Trials for Plecanatide (DB13170)

IndicationStatusPhase
DBCOND0044250 (Irritable Bowel Syndrome Characterized by Constipation)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01722318The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)Treatment